Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Many calves develop pneumonia days before showing symptoms. Lung ultrasounds are helping veterinarians detect the hidden ...

The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...

Investing.com -- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares fell 10% in after-hours trading Thursday following the company’s announcement of a proposed public offering of common stock.

HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety ...

Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

The company's shares recently gained nearly 10% in a week, closing at 87.00 EUR, as it presented compelling evidence for its strategic shift into oncology. The most striking data came from a Phase 2 ...

Trevi Therapeutics, Inc. TRVI shares are trading higher after the company announced the pricing of its $150 million offering ...

CytomX Therapeutics’ latest earnings call struck an upbeat tone as management highlighted robust efficacy signals, improving safety, and a clearer path toward registration for Varseta‑M in metastatic ...

BioNTech and DualityBio reported encouraging Phase 2 results for trastuzumab pamirtecan, an investigational HER2-targeted ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.